Please login to bookmark Close

Swiss drug maker Novartis has lost its bid to have Pharmacor’s Valtresto trade mark removed for non use, with an IP Australia delegate finding that an injunction in a fight over the patent for Novartis’ heart drug Entresto was an obstacle to using the mark. 

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au